The following table sets forth the computation of basic and diluted EPS (shares in thousands):

	Three Months Ended December 31,						Nine Months Ended December 31,

	2011			2010			2011			2010
Computation of Basic EPS:
Net income (loss)	$	14,104		$	40,859		$	(41,980	)	$	70,512
Less: net income allocated to participating securities		(939	)		(2,641	)		—			(4,787	)

Net income (loss) for basic EPS calculation	$	13,165		$	38,218		$	(41,980	)	$	65,725

Total weighted average shares outstanding—basic		89,523			86,321			83,003			85,783
Less: weighted average participating shares outstanding		(5,958	)		(5,578	)		—			(5,824	)

Weighted average common shares outstanding—basic		83,565			80,743			83,003			79,959

Basic EPS	$	0.16		$	0.47		$	(0.51	)	$	0.82

Computation of Diluted EPS:
Net income (loss)	$	14,104		$	40,859		$	(41,980	)	$	70,512
Less: net income allocated to participating securities		(939	)		(2,641	)		—			(4,787	)
Add: interest expense, net of tax, on Convertible Notes		—			3,552			—			10,446

Net income (loss) for diluted EPS calculation	$	13,165		$	41,770		$	(41,980	)	$	76,171

Weighted average common shares outstanding—basic		83,565			80,743			83,003			79,959
Add: dilutive effect of common stock equivalents		—			12,939			—			12,938

Weighted average common shares outstanding—diluted		83,565			93,682			83,003			92,897

Diluted EPS	$	0.16		$	0.45		$	(0.51	)	$	0.82

The Company incurred a net loss for the nine months ended December 31, 2011; therefore, the basic and diluted weighted average shares outstanding exclude the impact of unvested share-based awards that are considered participating restricted stock and all common stock equivalents because their impact would be antidilutive.

Our unvested restricted stock rights (including restricted stock units, time-based and market-based restricted stock awards) are considered participating restricted stock since these securities have non-forfeitable rights to dividends or dividend equivalents during the contractual period of the award, and thus require the two-class method of computing EPS. The calculation of EPS for common stock shown above excludes the income attributable to the unvested restricted stock rights from the numerator and excludes the dilutive impact of those awards from the denominator. For the nine months ended December 31, 2011, we had 6,225,000 of unvested share-based awards that are considered participating restricted stock which are excluded due to the net loss for that period.

The Company defines common stock equivalents as unexercised stock options, common stock equivalents underlying the Convertible Notes (see Note 9) and warrants outstanding during the period. Common stock equivalents are measured using the treasury stock method, except for the Convertible Notes, which are assessed for their impact on diluted EPS using the more dilutive of the treasury stock method or the if-converted method. Under the provisions of the if-converted method, the Convertible Notes are assumed to be converted and included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Notes is added back to the numerator.

In connection with the issuance of our 4.375% Convertible Notes in June 2009, the Company purchased convertible note hedges (see Note 9) which were excluded from the calculation of diluted EPS because their impact is always considered antidilutive since the call option would be exercised by the Company when the exercise price is lower than the market price. Also in connection with the issuance of our 4.375% Convertible Notes, the Company entered into warrant transactions (see Note 9). For the three months ended December 31, 2011 and for the three months and nine months ended December 31, 2010, the Company excluded the warrants outstanding from its diluted EPS because the warrants' strike price of $14.945 was greater than the average market price of our common stock.

Other common stock equivalents excluded from the diluted EPS calculation were unexercised stock option awards of approximately 2,293,000 for the nine months ended December 31, 2011 because their effect would be antidilutive. For the three months ended December 31, 2011 and for the three months and nine months ended December 31, 2010, the Company excluded from its diluted EPS calculation approximately 2,293,000 and 2,386,000 of common stock equivalents which were antidilutive because the common stock equivalents' exercise prices exceeded the average fair market value of the Company's common stock.

For the three and nine months ended December 31, 2011, we issued approximately 2,773,000 and 2,917,000 shares, respectively, of common stock in connection with restricted stock awards. During the three and nine months ended December 31, 2011, we canceled 8,000 and 116,000 shares, respectively, of unvested restricted stock awards.